<DOC>
	<DOCNO>NCT00823368</DOCNO>
	<brief_summary>The subject meet inclusion exclusion criterion consent participate protocol 22001 offer participation 22001A evaluate secrete protein treatment STX209 placebo determine correlate effectiveness treatment susceptibility treatment STX209 . These subject also ask contribute blood sample DNA ( deoxyribonucleic acid ) collection . The investigator study DNA determine STX209 work well people specific gene variation , find new gene variation predict well STX209 work .</brief_summary>
	<brief_title>Biomarker Testing DNA Collection Subjects Participating Protocol 22001</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fragile X Syndrome</mesh_term>
	<criteria>Subjects meet inclusion exclusion criterion consent participate protocol 22001 Subjects meet inclusion exclusion criterion consent participate protocol 22001</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>fragile X syndrome</keyword>
	<keyword>biomarkers</keyword>
</DOC>